Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 1997

View Archived Issues

Cell adhesion inhibitors claimed by Nippon Shinyaku

Toyama discloses antiplatelet agents

ACAT inhibitors from Takeda

SmithKline Beecham reports new antiinflammatory/antiallergic agents

New COX-2 inhibitor series disclosed by Merck Frosst

5-HT3/5-HT4 receptor ligands disclosed by Synthelabo

New antiasthma agents from Tanabe Seiyaku

NIH continues pivotal HIV-IG trial

Neurex compound headed for pivotal trials in head trauma

Glaxo Wellcome claims new formulation of anxiolytic agent

Almirall and Prodesfarma heading for merger

Panax and Sangen to combine

Raloxifene for inhibition of vascular smooth muscle cell migration

Smoking definitively linked to cardiovascular morbidity and mortality

MAb from Hayashibara with IFN-inducing properties

Clinical results of gabapentin in ALS reported

Inhibitors of alpha-amylase disclosed by Japanese researchers

Eisai discloses IL-1 inhibitors

Connective Therapeutics advances development of interferon

BMS cognition enhancer not superior to placebo in clinical study

New AMPA receptor modulator described by Servier

TBC receives patent coverage for endothelin antagonists

New tool for studying phosphodiesterase receptors

FDA expands orphan drug designation for NTZ

Labopharm and Sepracor to develop solid oral form of levalbuterol

ID Biomedical developing TB test

NIH offers licenses for conjugate vaccine

NIH seeks licensees for dopamine reuptake inhibitors

NIH offers licenses for IDDM markers

NIH seeks licensees for perilipins

Collaborators sought for gene therapy technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.